| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 48 (2022):ID 769-775 |doi: 10.2306/scienceasia1513-1874.2022.119

VASH2 promotes oxaliplatin resistance in gastric cancer cells via the AKT signaling pathway

Baoli Lin, Zhi Chen*

ABSTRACT:     Gastric cancer (GC) is one of the most common malignant tumors worldwide. GC cells are sensitive to chemotherapy drugs such as oxaliplatin (OHP, trans -/- diaminocyclohexane oxaliplatin or L-OHP). The molecular mechanisms involved in regulation of L-OHP resistance remain unknown. Vasohibin 2 (VASH2), a member of the vasohibin (VASH) family, has been implicated in chemical resistance in several cancer types. However, the possible role of VASH2 in the oxaliplatin resistance of GC is still unclear. In this study, we constructed two L-OHP resistance GC cell lines and found that VASH2 was highly expressed in L-OHP-treated GC cells. Downregulation of VASH2 suppressed the viability of L-OHP-treated GC cells. In addition, VASH2 knockdown stimulated the apoptosis of two oxaliplatin-resistant GC cell lines. In conclusion, our results suggested that VASH2 promoted oxaliplatin resistance in GC cells through the serthreonine protein kinase AKT pathway.

Download PDF

43 Downloads 1086 Views

a Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, Zhejiang 325000 China

* Corresponding author, E-mail: chenzhi11213@163.com

Received 20 Dec 2021, Accepted 30 May 2022